Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2009 1
2010 1
2012 2
2013 1
2014 1
2015 1
2016 1
2017 2
2018 5
2019 2
2020 5
2021 7
2022 11
2023 11
2024 18
2025 21
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M; ZeNix Trial Team. Conradie F, et al. N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430. N Engl J Med. 2022. PMID: 36053506 Free PMC article. Clinical Trial.
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. ...We randomly assigned the participants to receiv …
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tubercu …
Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
Wang M, Men P, Zhang W, Wu J, Gu Y, Wang F, Huang H, Yu X, Duan H. Wang M, et al. J Glob Antimicrob Resist. 2024 Jun;37:135-140. doi: 10.1016/j.jgar.2024.03.009. Epub 2024 Mar 30. J Glob Antimicrob Resist. 2024. PMID: 38561143 Free article.
OBJECTIVE: This study aims to estimate the overall in vitro activity of bedaquiline (BDQ) against clinical isolates of Mycobacterium abscessus complex (MABS) and M. avium complex (MAC), considering BDQ as a repurposed drug for non-tuberculous mycobacteria (NTM) infections. …
OBJECTIVE: This study aims to estimate the overall in vitro activity of bedaquiline (BDQ) against clinical isolates of Mycobacterium …
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
Omar S, Whitfield MG, Nolan MB, Ngom JT, Ismail N, Warren RM, Klopper M. Omar S, et al. J Antimicrob Chemother. 2024 Feb 1;79(2):211-240. doi: 10.1093/jac/dkad372. J Antimicrob Chemother. 2024. PMID: 38134888 Free PMC article.
A meta-analysis of bedaquiline efficacy against NTM infections in animal models was performed. Culture conversion, cure and/or relapse-free cure were used to evaluate the efficacy of bedaquiline in treating NTM infection in humans. RESULTS: Fifty studies met the inc …
A meta-analysis of bedaquiline efficacy against NTM infections in animal models was performed. Culture conversion, cure and/or relaps …
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, Migliori GB, Nasiri MJ. Hatami H, et al. J Bras Pneumol. 2022 May 30;48(2):e20210384. doi: 10.36416/1806-3756/e20210384. eCollection 2022. J Bras Pneumol. 2022. PMID: 35649043 Free PMC article.
The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. METHODS: This was a systematic review and meta-analysis of studies published up to March 15, 2021. ...CONCLUSIONS: In patients with MDR-TB receiving bedaqui …
The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. METHODS: This was a …
Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis.
Hu X, Wu Z, Lei J, Zhu Y, Gao J. Hu X, et al. BMC Infect Dis. 2025 May 12;25(1):689. doi: 10.1186/s12879-025-11067-2. BMC Infect Dis. 2025. PMID: 40355818 Free PMC article.
BACKGROUND: Drug-resistant tuberculosis (TB) remains a major global public health challenge. While bedaquiline (BDQ) offers improved treatment outcomes for patients with multi-drug resistant TB (MDR-TB), its widespread use has led to the emergence of BDQ resistance. ...
BACKGROUND: Drug-resistant tuberculosis (TB) remains a major global public health challenge. While bedaquiline (BDQ) offers improved …
Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Cheraghi M, Amiri M, Andarzgoo S, Zarei F, Seghatoleslami ZS, Centis R, Visca D, D'Ambrosio L, Pontali E, Nasiri MJ, Migliori GB. Cheraghi M, et al. J Bras Pneumol. 2025 Mar 31;51(1):e20240391. doi: 10.36416/1806-3756/e20240391. eCollection 2025. J Bras Pneumol. 2025. PMID: 40172415 Free PMC article.
This systematic review and meta-analysis sought to examine the efficacy of linezolid (LZD) and bedaquiline (BDQ) in MDR-TB treatment regimens, evaluating their roles in enhancing therapeutic success and informing optimized management of MDR-TB. ...
This systematic review and meta-analysis sought to examine the efficacy of linezolid (LZD) and bedaquiline (BDQ) in MDR-TB treatment …
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, Daniel BD, Dave JD, Vadgama P, Ramraj B, Kant S, Bhatnagar AK, Shanmugam S, Paul D, Bharathi J, Palav M, Shah NV, Santhanakrishnan R, Dewan RK, Shekh N, Rathinam P, Sisara AB, Mankar SD, Bajpai J, Mittal U, Chauhan S, Kumar R, Parmar M, Mattoo SK, Jaju J; modified BPaL (mBPaL) Study Team. Padmapriyadarsini C, et al. Clin Infect Dis. 2024 Dec 17;79(6):1375-1385. doi: 10.1093/cid/ciae388. Clin Infect Dis. 2024. PMID: 39194339 Clinical Trial.
BACKGROUND: Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration. ...Patients were randomized to 26 weeks o …
BACKGROUND: Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment ef …
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
BACKGROUND: Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolone) is difficult to treat. endTB-Q aimed to evaluate the efficacy and safety of bedaquiline, delamanid, linezol …
BACKGROUND: Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistanc …
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH; SimpliciTB Consortium. Cevik M, et al. Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17. Lancet Infect Dis. 2024. PMID: 38768617 Free article. Clinical Trial.
Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) regimen was identified with treatment-shortening potential for both drug-susceptible (DS) and drug-resistant (DR) TB. .. …
Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and p …
85 results